---
title: Peptide Manufacturing Database
description: Comprehensive database of peptide synthesis, purification, characterization, formulation, and quality control processes
category: Peptide Manufacturing
version: "1.0.0"
lastUpdated: "2026-06-13"
totalProcesses: 35
categories:
  - name: Synthesis
    count: 10
    description: Peptide bond formation and chain assembly methods
  - name: Purification
    count: 10
    description: Isolation and separation of target peptides
  - name: Characterization
    count: 5
    description: Structural and compositional analysis
  - name: Formulation
    count: 5
    description: Drug product development and delivery
  - name: Quality Control
    count: 5
    description: Testing and compliance verification
---

# Peptide Manufacturing Database

This database catalogs 35 essential processes used in modern peptide manufacturing, from synthesis through quality control.

---

## Synthesis Processes

### SPPS (Solid Phase Peptide Synthesis)

```yaml
id: SYN-001
process_name: Solid Phase Peptide Synthesis (SPPS)
description: >
  Standard method for peptide synthesis using an insoluble resin support.
  Amino acids are sequentially added to a growing chain anchored to polymeric
  beads, enabling excess reagent use and simplified purification via filtration.
  The two main strategies are Fmoc (base-labile) and Boc (acid-labile) protection.
equipment:
  - Automated peptide synthesizer
  - Reaction vessels (glass or polypropylene)
  - Filtration apparatus
  - Vacuum manifold
  - Shaker or orbital mixer
reagents:
  - Protected amino acids (Fmoc or Boc)
  - Resin (Wang, Rink amide, MBHA, Tentagel)
  - Coupling reagents (HBTU, HATU, PyBOP, DIC/HOBt)
  - Deprotection agents (piperidine for Fmoc, TFA for Boc)
  - Solvents (DMF, NMP, DCM)
  - Capping agents (acetic anhydride)
  - Cleavage cocktail (TFA, scavengers)
conditions:
  - Temperature: Room temperature (20-25°C)
  - Coupling time: 30-120 min per residue
  - Deprotection time: 5-20 min
  - Agitation: Gentle mixing or bubbling nitrogen
  - Atmosphere: Inert (nitrogen or argon)
scale:
  bench: 0.1-1 mmol
  pilot: 1-100 mmol
  production: 100-1000 mmol
yield:
  per_coupling: 99.0-99.7%
  overall_20mer: 60-80%
  overall_50mer: 10-40%
purity:
  crude: 60-90%
  after_purification: 95-99%
quality_control:
  - Kaiser test (ninhydrin) for coupling completion
  - Chloranil test for secondary amino acids
  - UV monitoring of Fmoc deprotection
  - Mass spectrometry (ESI-MS, MALDI-TOF)
  - Analytical HPLC
  - Amino acid analysis
regulatory_requirements:
  - GMP compliance for API production
  - ICH Q7 (API manufacturing)
  - ICH Q11 (starting materials)
  - Resin characterization and lot testing
  - Solvent recovery and disposal (EPA, REACH)
category: Synthesis
tags: [solid-phase, Fmoc, Boc, resin, automated]
```

---

### LPPS (Liquid Phase Peptide Synthesis)

```yaml
id: SYN-002
process_name: Liquid Phase Peptide Synthesis (LPPS)
description: >
  Solution-phase peptide synthesis using classical organic chemistry techniques.
  Each coupling step is performed in homogeneous solution, followed by purification
  via extraction or crystallization. Preferred for shorter peptides and when
  scale-up economics favor solution-phase processing.
equipment:
  - Glass reaction vessels
  - Rotary evaporator
  - Extraction separatory funnels
  - Filtration apparatus
  - Temperature-controlled jacketed reactors
reagents:
  - Protected amino acids (Z, Boc, Fmoc)
  - Coupling reagents (DCC, EDC, HOBt)
  - Solvents (THF, DCM, ethyl acetate, DMF)
  - Bases (TEA, DIPEA)
  - Deprotection agents (HBr/AcOH, Pd/C, piperidine)
conditions:
  - Temperature: -20°C to room temperature
  - Coupling time: 1-6 hours
  - Reactions performed under inert atmosphere
  - pH control critical for selectivity
scale:
  bench: 1-10 g
  pilot: 10-1000 g
  production: 1-100 kg
yield:
  per_coupling: 95-99%
  overall_10mer: 70-85%
  overall_20mer: 40-60%
purity:
  crude: 70-90%
  after_purification: 95-99%
quality_control:
  - TLC monitoring
  - HPLC analysis
  - Mass spectrometry
  - NMR spectroscopy
  - Chiral purity testing
regulatory_requirements:
  - GMP compliance
  - Solvent residue limits (ICH Q3C)
  - Impurity profiling (ICH Q3A)
  - Starting material qualification
category: Synthesis
tags: [liquid-phase, solution, classical, large-scale]
```

---

### Recombinant Expression

```yaml
id: SYN-003
process_name: Recombinant Expression
description: >
  Biological production of peptides using genetically engineered host organisms.
  The peptide gene is cloned into expression vectors and produced in E. coli,
  yeast (Pichia pastoris, S. cerevisiae), or mammalian cells (CHO, HEK293).
  Enables production of complex, folded peptides and proteins with
  post-translational modifications when using eukaryotic hosts.
equipment:
  - Bioreactors (stirred tank, wave, hollow fiber)
  - Fermenters (for microbial culture)
  - Incubators and shakers
  - Centrifuges (for cell harvest)
  - Homogenizers (cell lysis)
  - Chromatography systems
reagents:
  - Expression vectors (pET, pGAP, pcDNA)
  - Host cells (E. coli BL21, Pichia pastoris GS115, CHO-K1)
  - Growth media (LB, TB, minimal media, CD-CHO)
  - Antibiotics (ampicillin, kanamycin)
  - Inducers (IPTG, methanol, galactose)
  - Protease inhibitors
conditions:
  - E. coli: 37°C, pH 7.0, 4-16h induction
  - Pichia: 28-30°C, pH 5.0-6.0, 72-120h
  - Mammalian: 37°C, pH 6.8-7.2, 7-14 days
  - DO: 20-40% saturation
  - Agitation: 100-1000 rpm (scale dependent)
scale:
  bench: 0.1-10 L
  pilot: 10-500 L
  production: 500-15000 L
yield:
  ecoli_inclusion_bodies: 0.5-5 g/L
  ecoli_soluble: 0.05-0.5 g/L
  yeast: 0.1-2 g/L
  mammalian: 0.01-1 g/L
purity:
  crude_extract: 5-30%
  after_purification: 90-99%
quality_control:
  - SDS-PAGE
  - Western blot
  - Mass spectrometry
  - Endotoxin testing (LAL)
  - Host cell protein (HCP) ELISA
  - Residual DNA quantification
  - Mycoplasma testing (mammalian)
regulatory_requirements:
  - ICH Q5A (viral safety)
  - ICH Q5B (expression construct)
  - ICH Q5D (cell substrates)
  - FDA 21 CFR 610 (biological products)
  - EU GMP Annex 2 (biological medicinal products)
  - Adventitious agent testing
category: Synthesis
tags: [recombinant, biological, E. coli, yeast, mammalian]
```

---

### Cell-Free Synthesis

```yaml
id: SYN-004
process_name: Cell-Free Synthesis
description: >
  In vitro translation using cell lysates or reconstituted translation systems
  to produce peptides without living cells. Uses purified ribosomes, tRNA
  synthetases, and energy regeneration systems. Enables incorporation of
  non-natural amino acids and rapid prototyping of peptide sequences.
equipment:
  - Incubators (30-37°C)
  - Water baths
  - Dialysis systems (for continuous exchange)
  - Microplate readers (for monitoring)
  - Centrifuges
reagents:
  - Cell lysate (E. coli S30, wheat germ, rabbit reticulocyte)
  - Template DNA or mRNA
  - Amino acids (natural and non-natural)
  - tRNA (total or specific)
  - Energy regeneration system (creatine kinase, pyruvate kinase)
  - NTPs (ATP, GTP, CTP, UTP)
  - Ribonucleotides and cofactors
conditions:
  - Temperature: 25-37°C (lysate dependent)
  - Reaction time: 30 min - 6 hours
  - pH: 7.0-8.0
  - Mg2+ concentration: 2-12 mM (critical)
  - K+ concentration: 80-200 mM
scale:
  analytical: 10-100 µL
  bench: 0.1-10 mL
  pilot: 10-100 mL
yield:
  batch: 0.01-0.1 mg/mL
  continuous_exchange: 0.1-2 mg/mL
  pcf_system: 0.5-6 mg/mL
purity:
  crude: 10-50%
  after_purification: 85-98%
quality_control:
  - Mass spectrometry confirmation
  - SDS-PAGE analysis
  - Fluorescence detection (labeled products)
  - Functional assays (if applicable)
  - Endotoxin measurement
regulatory_requirements:
  - GMP not typically applied (research/development)
  - Reagent qualification required
  - Template sequence verification
  - Product characterization documentation
category: Synthesis
tags: [cell-free, in-vitro, translation, non-natural-amino-acids]
```

---

### Enzymatic Synthesis

```yaml
id: SYN-005
process_name: Enzymatic Synthesis
description: >
  Protease-catalyzed peptide bond formation using thermodynamic or kinetic
  control. Proteases such as subtilisin, thermolysin, and papain catalyze
  the reverse reaction (synthesis) under controlled conditions. Offers
  stereoselectivity, mild reaction conditions, and green chemistry advantages.
equipment:
  - Jacketed reactors with temperature control
  - pH-stat controllers
  - Membrane reactors
  - HPLC systems (monitoring)
  - Lyophilizers
reagents:
  - Proteases (subtilisin, thermolysin, papain, chymotrypsin)
  - Protected amino acid esters or amides
  - Nucleophile (amino acid or peptide)
  - Organic cosolvents (DMF, DMSO, ethanol)
  - Buffer solutions
  - Immobilization supports (if using immobilized enzyme)
conditions:
  - Temperature: 25-60°C (enzyme dependent)
  - pH: 6.0-9.0
  - Reaction time: 2-72 hours
  - Cosolvent: 10-50% organic modifier
  - Substrate concentration: 50-500 mM
scale:
  bench: 0.1-10 g
  pilot: 10-500 g
  production: 0.5-50 kg
yield:
  thermodynamic: 30-70%
  kinetic_with_acyl_donor: 60-95%
purity:
  crude: 60-85%
  after_purification: 90-99%
quality_control:
  - Enzyme activity assay
  - Substrate conversion monitoring
  - HPLC analysis
  - Chiral purity (no racemization)
  - Mass spectrometry
regulatory_requirements:
  - Enzyme source qualification (GRAS status)
  - Residual enzyme activity limits
  - ICH Q6A (specifications)
  - Solvent residue limits
category: Synthesis
tags: [enzymatic, protease, green-chemistry, stereoselective]
```

---

### Microwave-Assisted Synthesis

```yaml
id: SYN-006
process_name: Microwave-Assisted Synthesis
description: >
  SPPS accelerated by microwave irradiation for rapid heating and enhanced
  coupling efficiency. Microwave energy provides uniform, rapid heating that
  reduces coupling times, improves yields for difficult sequences, and minimizes
  aggregation. Particularly beneficial for long or aggregation-prone peptides.
equipment:
  - Microwave peptide synthesizer (CEM Liberty, Biotage Initiator)
  - Single-mode microwave cavity
  - Temperature and pressure sensors
  - Automated reagent delivery
  - Resin filtration module
reagents:
  - Same as standard SPPS
  - Fmoc-amino acids
  - Rink amide or Wang resin
  - Coupling reagents (HATU, HBTU)
  - DMF, piperidine
  - Microwave-transparent solvents
conditions:
  - Microwave power: 20-50 W
  - Temperature: 50-90°C
  - Coupling time: 2-10 min (vs 30-120 min conventional)
  - Deprotection time: 2-5 min
  - Cooling between cycles
scale:
  research: 0.025-0.1 mmol
  process: 0.1-1 mmol
yield:
  per_coupling: 99.2-99.8%
  overall_30mer: 50-75%
  overall_50mer: 15-40%
purity:
  crude: 65-90%
  after_purification: 95-99%
quality_control:
  - UV monitoring (Fmoc deprotection)
  - Kaiser test
  - Mass spectrometry
  - Analytical HPLC
  - Aggregation assessment
regulatory_requirements:
  - Same as standard SPPS
  - Process validation for microwave parameters
  - Equipment qualification (IQ/OQ/PQ)
category: Synthesis
tags: [microwave, accelerated, automated, difficult-sequences]
```

---

### Flow Chemistry Synthesis

```yaml
id: SYN-007
process_name: Flow Chemistry Synthesis
description: >
  Continuous flow peptide synthesis in microreactors or flow columns. Reagents
  are pumped through immobilized resin columns or solution-phase reactors with
  precise temperature, pressure, and residence time control. Offers improved
  mixing, heat transfer, safety, and scalability compared to batch processes.
equipment:
  - Flow reactors (microreactors, packed bed columns)
  - HPLC pumps (high precision)
  - Back pressure regulators
  - In-line UV/IR detectors
  - Automated fraction collectors
  - Temperature control modules
reagents:
  - Protected amino acids in solution
  - Immobilized resin (packed columns)
  - Coupling reagents
  - Deprotection agents
  - Solvents (anhydrous DMF, NMP)
conditions:
  - Flow rate: 0.1-10 mL/min
  - Temperature: 20-80°C
  - Residence time: 1-30 min per step
  - Pressure: 1-20 bar
  - In-line monitoring (UV, MS)
scale:
  analytical: 0.001-0.01 mmol/h
  bench: 0.01-1 mmol/h
  production: 1-100 mmol/h
yield:
  per_coupling: 98.5-99.5%
  overall_20mer: 70-85%
purity:
  crude: 70-90%
  after_purification: 95-99%
quality_control:
  - In-line UV monitoring
  - In-line mass spectrometry
  - Real-time HPLC sampling
  - Automated fraction analysis
  - Process analytical technology (PAT)
regulatory_requirements:
  - Process validation (ICH Q8)
  - Real-time release testing potential
  - Continuous process verification
  - Equipment qualification
  - Data integrity (21 CFR Part 11)
category: Synthesis
tags: [flow, continuous, microreactor, process-intensification]
```

---

### Fragment Condensation

```yaml
id: SYN-008
process_name: Fragment Condensation
description: >
  Convergent synthesis strategy where peptide fragments are synthesized
  separately (typically by SPPS) then condensed in solution or on solid phase.
  Reduces overall synthetic burden for long peptides. Fragments are designed
  with orthogonal protecting groups for selective activation and ligation.
equipment:
  - SPPS synthesizers (fragment preparation)
  - HPLC systems (fragment purification)
  - Reaction vessels (condensation)
  - Freeze dryers
  - Analytical instruments
reagents:
  - Protected peptide fragments (10-20 residues)
  - Coupling reagents (HATU, PyBOP, EDC)
  - Racemization suppressants (HOBt, Oxyma)
  - Solvents (DMF, NMP, DCM)
  - Selective deprotection agents
conditions:
  - Fragment coupling: 0-25°C, 2-24 hours
  - Fragment concentration: 5-50 mM
  - Stoichiometry: 1.1-2.0 equiv activated fragment
  - pH control critical
scale:
  bench: 0.01-1 g
  pilot: 1-100 g
  production: 100 g - 10 kg
yield:
  per_fragment_coupling: 70-95%
  convergent_40mer: 40-70%
purity:
  crude: 50-80%
  after_purification: 90-99%
quality_control:
  - Mass spectrometry (each fragment and final product)
  - HPLC purity
  - Amino acid analysis
  - Chiral integrity
  - Sequence confirmation (Edman or MS/MS)
regulatory_requirements:
  - GMP for fragment synthesis
  - Fragment characterization documentation
  - Process validation for condensation
  - Impurity profile (segment deletion, racemization)
category: Synthesis
tags: [convergent, fragments, long-peptides, protected]
```

---

### Native Chemical Ligation

```yaml
id: SYN-009
process_name: Native Chemical Ligation (NCL)
description: >
  Chemoselective reaction between a C-terminal thioester and an N-terminal
  cysteine residue, forming a native peptide bond at the ligation site.
  Enables synthesis of proteins (>100 residues) by ligating unprotected
  peptide segments in aqueous solution. The reaction proceeds through a
  transthioesterification followed by S-to-N acyl shift.
equipment:
  - Reaction vessels (glass or polypropylene)
  - HPLC systems (monitoring and purification)
  - Shakers or rotators
  - Lyophilizers
  - UV spectrometers
reagents:
  - Peptide with C-terminal thioester (alkyl, aryl, or crypto-thioesters)
  - Peptide with N-terminal cysteine
  - Thiol catalyst (MPAA, MESNA, thiophenol)
  - Denaturant (guanidine-HCl or urea)
  - Reducing agent (TCEP, DTT)
  - Buffer (phosphate, pH 6.0-7.5)
conditions:
  - Temperature: 20-37°C
  - pH: 6.0-7.5
  - Reaction time: 2-48 hours
  - Peptide concentration: 0.1-5 mM
  - Thiol catalyst: 1-5% (v/v or w/v)
  - Denaturant: 2-6 M
scale:
  bench: 0.01-100 mg
  pilot: 100 mg - 10 g
  production: 1-100 g
yield:
  ligation: 60-95%
  with_desulfurization: 50-85%
purity:
  crude: 50-80%
  after_purification: 90-99%
quality_control:
  - Mass spectrometry (ligation product)
  - Analytical HPLC
  - Thiol quantification (Ellman's test)
  - Sequence verification
  - Disulfide bond analysis
regulatory_requirements:
  - GMP for segment synthesis
  - Ligation reaction validation
  - Residual thiol limits
  - Product characterization
  - ICH Q6A specifications
category: Synthesis
tags: [NCL, chemoselective, protein-synthesis, thioester, cysteine]
```

---

### Click Chemistry

```yaml
id: SYN-0010
process_name: Click Chemistry (CuAAC Conjugation)
description: >
  Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) forming 1,4-disubstituted
  1,2,3-triazole linkages. Used for peptide conjugation, macrocyclization,
  labeling, and bioconjugation. The triazole mimics amide bond geometry and is
  resistant to hydrolysis, proteolysis, and oxidation.
equipment:
  - Reaction vessels (inert atmosphere)
  - HPLC systems
  - Lyophilizers
  - UV-Vis spectrometers
  - NMR (for characterization)
reagents:
  - Azide-functionalized peptide
  - Alkyne-functionalized peptide
  - Copper(I) source (CuSO4 + sodium ascorbate, or CuBr)
  - Ligand (TBTA, THPTA, BTTAA)
  - Solvents (t-BuOH/H2O, DMF/H2O)
  - Reducing agent (sodium ascorbate)
  - Chelating resin (for Cu removal)
conditions:
  - Temperature: 20-40°C
  - Reaction time: 1-24 hours
  - Cu(I) concentration: 0.1-1.0 equiv
  - Ligand:Cu ratio: 1:1 to 5:1
  - pH: 5-8 (buffer dependent)
  - Oxygen exclusion required
scale:
  bench: 0.01-1 g
  pilot: 1-100 g
  production: 100 g - 10 kg
yield:
  conjugation: 80-99%
  macrocyclization: 50-90%
purity:
  crude: 60-85%
  after_purification: 90-99%
quality_control:
  - Mass spectrometry (triazole formation)
  - HPLC analysis
  - Residual copper quantification (ICP-MS)
  - NMR (regioselectivity confirmation)
  - UV-Vis (click reaction monitoring)
regulatory_requirements:
  - Residual copper limits (ICH Q3D)
  - Process validation
  - Impurity profiling (regioisomers)
  - ICH Q3A/Q3B (impurities)
  - Biocompatibility assessment (if therapeutic)
category: Synthesis
tags: [click, CuAAC, conjugation, triazole, bioconjugation]
```

---

## Purification Processes

### RP-HPLC (Reverse Phase High Performance Liquid Chromatography)

```yaml
id: PUR-011
process_name: Reverse Phase HPLC (RP-HPLC)
description: >
  Primary purification method for synthetic peptides using hydrophobic
  interactions with C8 or C18 bonded stationary phases. Peptides elute
  in order of increasing hydrophobicity with aqueous-organic gradients.
  Industry standard for final polishing of crude peptides to >95% purity.
equipment:
  - Preparative HPLC system (Waters, Agilent, Knauer)
  - Columns: C18, C8, C4 (4-50 mm ID, 10-25 cm length)
  - UV detector (214, 220, 280 nm)
  - Fraction collector
  - Binary or quaternary gradient pump
reagents:
  - Mobile phase A: 0.1% TFA in water
  - Mobile phase B: 0.1% TFA in acetonitrile
  - Alternative ion-pairing agents (HFBA, TEAP, ammonium acetate)
  - Acetonitrile (HPLC grade)
  - Water (Milli-Q or equivalent)
conditions:
  - Flow rate: 1-200 mL/min (scale dependent)
  - Gradient: 5-60% B over 20-60 min
  - Temperature: 20-40°C
  - Detection: UV 214-220 nm
  - Pressure: 100-400 bar
scale:
  analytical: 1-100 µg
  semiprep: 1-100 mg
  prep: 100 mg - 10 g
  production: 10-1000 g
yield:
  recovery: 70-95%
purity:
  achieved: 95-99.9%
quality_control:
  - Peak purity analysis (DAD, MS)
  - Retention time consistency
  - Plate count and resolution
  - System suitability testing
  - Fraction analysis by LC-MS
regulatory_requirements:
  - Method validation (ICH Q2)
  - Column qualification and lifetime studies
  - Solvent recycling validation
  - Data integrity compliance
category: Purification
tags: [HPLC, reverse-phase, C18, preparative, polishing]
```

---

### IEX (Ion Exchange Chromatography)

```yaml
id: PUR-012
process_name: Ion Exchange Chromatography (IEX)
description: >
  Separation based on electrostatic interactions between charged peptide
  groups and oppositely charged stationary phase. Cation exchange (CM, SP)
  for basic peptides (pI >7), anion exchange (DEAE, Q) for acidic peptides
  (pI <7). High selectivity for charge variants and excellent scalability.
equipment:
  - Chromatography system (ÄKTA, Bio-Rad)
  - Columns: Cation exchange (CM Sepharose, SP Sepharose)
  - Columns: Anion exchange (DEAE Sepharose, Q Sepharose)
  - UV detector, conductivity meter
  - pH monitor
  - Fraction collector
reagents:
  - Buffers: sodium phosphate, Tris-HCl, ammonium acetate
  - NaCl gradient (0-1 M) or pH gradient
  - Regeneration: NaOH (1 M)
  - Sanitization: 0.5-1 M NaOH
  - Equilibration buffer
conditions:
  - pH: 4-10 (buffer dependent)
  - Ionic strength: 0-1 M NaCl gradient
  - Flow rate: 1-500 mL/min
  - Temperature: 4-25°C
  - Loading capacity: 10-50 mg/mL resin
scale:
  analytical: 1-100 mg
  prep: 100 mg - 100 g
  production: 100 g - 10 kg
yield:
  recovery: 75-95%
purity:
  achieved: 90-99%
quality_control:
  - SDS-PAGE analysis
  - Charge variant analysis
  - Host cell protein removal
  - Resin lifetime studies
  - Cleaning validation
regulatory_requirements:
  - Resin qualification (extractables/leachables)
  - Column sanitization validation
  - ICH Q6A specifications
  - Viral clearance (if biological)
category: Purification
tags: [ion-exchange, cation, anion, charge-based, scalable]
```

---

### SEC (Size Exclusion Chromatography)

```yaml
id: PUR-013
process_name: Size Exclusion Chromatography (SEC)
description: >
  Molecular sieve separation based on hydrodynamic volume. Larger molecules
  elute first as they cannot enter pore network. Used for desalting,
  buffer exchange, aggregate removal, and molecular weight determination.
  Non-adsorptive technique preserving native peptide structure.
equipment:
  - Chromatography system (ÄKTA, Waters)
  - Columns: Superdex, Sephadex, TSK-GEL
  - UV detector
  - Multi-angle light scattering (MALS) detector
  - Differential refractive index (dRI) detector
reagents:
  - Mobile phase: PBS, Tris, ammonium acetate, water
  - NaCl (0.1-0.5 M for ionic strength)
  - Column calibration standards
  - Molecular weight markers
conditions:
  - Isocratic elution
  - Flow rate: 0.1-100 mL/min
  - Temperature: 4-25°C
  - Sample concentration: 1-50 mg/mL
  - Injection volume: 0.5-5% of column volume
scale:
  analytical: 0.01-1 mg
  desalting: 1-500 mg
  prep: 100 mg - 50 g
  production: 10-500 g
yield:
  recovery: 85-98%
purity:
  aggregate_removal: 95-99% monomer
quality_control:
  - Molecular weight determination
  - Aggregate quantification
  - Column efficiency (plate count)
  - Resolution verification
  - MALS for absolute MW
regulatory_requirements:
  - SEC method validation (ICH Q2)
  - Column qualification
  - Aggregate limits (ICH Q6B)
  - Stability-indicating method
category: Purification
tags: [SEC, size-exclusion, desalting, aggregates, polishing]
```

---

### Affinity Purification

```yaml
id: PUR-014
process_name: Affinity Purification
description: >
  Highly selective purification using specific biological interactions.
  Tag-based systems include His-tag (IMAC), GST-tag, MBP-tag, Strep-tag,
  and FLAG-tag. Also used for antibody purification (Protein A/G) and
  enzyme substrates/inhibitors. One-step purification achieving >90% purity.
equipment:
  - ÄKTA or similar chromatography system
  - Affinity columns (Ni-NTA, Glutathione Sepharose, Protein A)
  - Gravity flow columns
  - Magnetic beads (small scale)
  - UV detector, fraction collector
reagents:
  - Affinity resin (Ni-NTA, Co-TAC, Glutathione, Protein A)
  - Binding buffer (PBS, Tris, imidazole-free)
  - Elution buffer (imidazole for His-tag, glutathione for GST)
  - Wash buffers
  - Regeneration agents (EDTA, NaOH, glycine)
conditions:
  - Binding: 4°C or room temperature, 30-60 min
  - Washing: 10-50 mM imidazole (His-tag)
  - Elution: 250-500 mM imidazole or low pH
  - Flow rate: 1-50 mL/min
  - Loading: 5-50 mg/mL resin
scale:
  analytical: 0.01-10 mg
  prep: 10 mg - 10 g
  production: 1-500 g
yield:
  recovery: 70-95%
purity:
  achieved: 85-99%
quality_control:
  - SDS-PAGE (purity, MW)
  - Western blot (identity)
  - Resin leakage (Ni, protein ligand)
  - Endotoxin testing
  - Functional activity assay
regulatory_requirements:
  - Resin extractables/leachables
  - Leached ligand limits
  - Viral clearance validation
  - ICH Q6B (biological products)
  - Tag removal validation (if cleaved)
category: Purification
tags: [affinity, IMAC, His-tag, GST, Protein-A, selective]
```

---

### Membrane Filtration

```yaml
id: PUR-015
process_name: Membrane Filtration (Tangential Flow Filtration)
description: >
  Crossflow filtration using semi-permeable membranes for concentration,
  diafiltration (buffer exchange), and size-based separation. Tangential
  flow prevents membrane fouling. Ultrafiltration (UF) retains peptide,
  microfiltration (MF) removes cells/debris.
equipment:
  - TFF system (Sartorius, Millipore, Pall)
  - Membrane cassettes (regenerated cellulose, PES)
  - Permeate collection vessel
  - Pressure gauges (transmembrane, retentate)
  - Flow meters
reagents:
  - Membranes: 1 kDa, 3 kDa, 5 kDa, 10 kDa, 30 kDa MWCO
  - Buffer for diafiltration
  - NaOH (0.1-0.5 M for CIP)
  - Water for injection (WFI)
conditions:
  - Transmembrane pressure: 0.5-5 bar
  - Crossflow rate: 1-10 L/min per m²
  - Temperature: 4-25°C
  - Concentration factor: 5-20x
  - Diafiltration volumes: 5-10 volumes
scale:
  lab: 10-500 mL
  pilot: 0.5-50 L
  production: 50-5000 L
yield:
  recovery: 85-98%
  flux: 1-100 LMH
purity:
  concentration: 95-99% retention
  diafiltration: >99% buffer exchange
quality_control:
  - Membrane integrity testing (bubble point)
  - Flux monitoring
  - Retentate and permeate analysis
  - Protein concentration (A280, BCA)
  - Endotoxin testing
regulatory_requirements:
  - Membrane validation (extractables/leachables)
  - Integrity testing (pre/post use)
  - Cleaning validation
  - WFI quality (USP <1231>)
  - Process validation
category: Purification
tags: [TFF, ultrafiltration, diafiltration, membrane, concentration]
```

---

### Crystallization

```yaml
id: PUR-016
process_name: Crystallization
description: >
  Solid-liquid separation based on differential solubility. Peptide is
  dissolved in good solvent then precipitated by anti-solvent addition,
  cooling, or evaporation. Crystalline form offers improved stability,
  defined solid form, and high purity through lattice exclusion of impurities.
equipment:
  - Jacketed crystallizers
  - Temperature control units
  - Agitators (impeller, anchor)
  - Vacuum filtration (Büchner)
  - Centrifuges (filter centrifuge)
  - Lyophilizers (if needed)
reagents:
  - Good solvents (water, DMSO, DMF, acetic acid)
  - Anti-solvents (ethanol, isopropanol, acetone, MTBE)
  - pH adjusting agents
  - Seed crystals (if available)
conditions:
  - Cooling rate: 0.1-1°C/min
  - Anti-solvent addition: 0.5-5 mL/min
  - Final temperature: 0-10°C
  - Agitation: 50-200 rpm
  - Supersaturation: 1.2-3.0 (metastable zone)
scale:
  bench: 1-100 g
  pilot: 100 g - 10 kg
  production: 10-500 kg
yield:
  crystallization: 60-95%
purity:
  achieved: 90-99.5%
quality_control:
  - Crystal form (PXRD, DSC)
  - Polymorph screening
  - Residual solvent (GC)
  - Particle size distribution
  - Moisture content (Karl Fischer)
regulatory_requirements:
  - Polymorph control (ICH Q6A)
  - Residual solvent limits (ICH Q3C)
  - Solid form characterization
  - Seeding strategy validation
category: Purification
tags: [crystallization, solid-form, polymorph, anti-solvent]
```

---

### Precipitation

```yaml
id: PUR-017
process_name: Precipitation
description: >
  Solubility-based separation where peptide is selectively precipitated
  from solution by salting-out, pH adjustment, or organic solvent addition.
  Used for initial capture, concentration, and bulk impurity removal.
  Scalable, cost-effective, and requires minimal equipment.
equipment:
  - Jacketed vessels
  - Centrifuges
  - Filtration apparatus
  - pH meters
  - Conductivity meters
reagents:
  - Ammonium sulfate (salting out)
  - Organic solvents (ethanol, acetone, acetonitrile)
  - Acids/bases for pH adjustment (HCl, NaOH, TFA)
  - Polyethylene glycol (PEG)
  - Trichloroacetic acid (TCA)
conditions:
  - Ammonium sulfate: 20-80% saturation
  - Organic solvent: 30-70% v/v
  - pH: 3.0-9.0 (peptide dependent)
  - Temperature: 0-25°C
  - Incubation: 1-24 hours
scale:
  bench: 1-100 g
  pilot: 100 g - 10 kg
  production: 10-500 kg
yield:
  recovery: 60-95%
purity:
  achieved: 50-90%
quality_control:
  - Solubility curve determination
  - Impurity distribution analysis
  - Protein concentration
  - SDS-PAGE
regulatory_requirements:
  - Process validation
  - Reproducibility studies
  - Solvent residue limits
  - Impurity carry-over assessment
category: Purification
tags: [precipitation, salting-out, capture, scalable]
```

---

### Extraction

```yaml
id: PUR-018
process_name: Liquid-Liquid Extraction
description: >
  Separation based on differential partitioning between two immiscible
  phases (typically aqueous-organic). Used for removing hydrophobic
  impurities, scavenging reagents, or partitioning peptides based on
  hydrophobicity. Supports phase diagrams for process optimization.
equipment:
  - Separatory funnels (batch)
  - Mixer-settlers (continuous)
  - Centrifugal contactors
  - Pulsed columns
reagents:
  - Organic solvents: ethyl acetate, DCM, butanol, MTBE
  - Aqueous buffers: phosphate, acetate, citrate
  - Ion-pairing agents
  - Salts (ammonium sulfate, NaCl)
conditions:
  - pH: 2-10 (peptide and impurity dependent)
  - Temperature: 4-25°C
  - Phase ratio: 1:1 to 1:5
  - Mixing time: 5-30 min
  - Settling time: 5-30 min
  - Extractions: 2-5 stages
scale:
  bench: 10 mL - 1 L
  pilot: 1-100 L
  production: 100-10000 L
yield:
  recovery: 70-95%
purity:
  achieved: 60-85%
quality_control:
  - Partition coefficient determination
  - Phase separation efficiency
  - Solvent residue analysis
  - Impurity tracking
regulatory_requirements:
  - Solvent residue limits (ICH Q3C)
  - Process validation
  - Partition coefficient documentation
  - Environmental impact assessment
category: Purification
tags: [extraction, liquid-liquid, partition, capture]
```

---

### Preparative Chromatography

```yaml
id: PUR-019
process_name: Preparative Chromatography
description: >
  Large-scale chromatographic separation using various modes (RP, IEX,
  HIC, mixed-mode) for industrial peptide purification. Continuous
  chromatography (MCSGP, Simulated Moving Bed) improves productivity
  and yield for difficult separations.
equipment:
  - Preparative chromatography systems (ÄKTA Pilot, Bio-Rad)
  - Columns: 5-80 cm diameter, 10-30 cm bed height
  - Continuous chromatography (MCSGP, SMB)
  - UV, conductivity, pH monitors
  - Automated fraction collection
reagents:
  - Stationary phases: C18, C8, ion exchangers, HIC resins
  - Mobile phases: as per mode (RP, IEX, HIC)
  - Cleaning agents (NaOH, ethanol)
conditions:
  - Flow rate: 50-5000 mL/min
  - Loading: 10-100 g/L resin
  - Temperature: 4-25°C
  - Pressure: max 100 bar
scale:
  prep: 1-100 g
  production: 100 g - 100 kg
yield:
  single_column: 70-90%
  continuous: 85-98%
purity:
  achieved: 90-99.5%
quality_control:
  - Peak purity (LC-MS)
  - Yield consistency
  - Resin lifetime
  - Process mass intensity
regulatory_requirements:
  - GMP compliance
  - Column qualification
  - Process validation (ICH Q8)
  - Resin reuse validation
  - Cleaning validation
category: Purification
tags: [preparative, large-scale, continuous, MCSGP, SMB]
```

---

### Electrophoresis

```yaml
id: PUR-020
process_name: Electrophoresis
description: >
  Separation based on electrophoretic mobility in an electric field.
  SDS-PAGE for analytical sizing, isoelectric focusing (IEF) for charge
  analysis, capillary electrophoresis (CE) for high-resolution analysis.
  Preparative scale using free-flow electrophoresis (FFE).
equipment:
  - Gel electrophoresis systems (SDS-PAGE, IEF)
  - Capillary electrophoresis (CE) instruments
  - Free-flow electrophoresis (FFE) units
  - Power supplies
  - UV/fluorescence detectors
  - Gel documentation systems
reagents:
  - SDS-PAGE: acrylamide, SDS, TEMED, APS
  - IEF: ampholytes, urea
  - CE: buffers (phosphate, borate, Tris)
  - Staining: Coomassie, silver stain, fluorescent dyes
  - MW markers
conditions:
  - SDS-PAGE: 100-200 V, 1-2 hours
  - CE: 10-30 kV, 20-60 min
  - IEF: 2000-5000 V, 2-4 hours
  - Temperature: 4-25°C
scale:
  analytical: µg-mg
  preparative_FFE: mg-g
yield:
  FFE_recovery: 50-80%
purity:
  analytical: detection only
  preparative: 80-95%
quality_control:
  - Migration time precision
  - Band resolution
  - Quantification (densitometry)
  - CE system suitability
regulatory_requirements:
  - CE method validation (ICH Q2)
  - System suitability criteria
  - Reference standard qualification
  - Electropherogram documentation
category: Purification
tags: [electrophoresis, SDS-PAGE, CE, IEF, analytical]
```

---

## Characterization Processes

### Mass Spectrometry

```yaml
id: CHR-021
process_name: Mass Spectrometry (MS)
description: >
  Determination of molecular weight and structural information using
  ionization (ESI, MALDI), mass analysis (TOF, quadrupole, orbitrap),
  and detection. Provides exact mass, sequence confirmation via MS/MS,
  and impurity identification. Essential for peptide identity confirmation.
equipment:
  - ESI-MS (LC-MS systems)
  - MALDI-TOF
  - Q-TOF, triple quadrupole
  - Orbitrap
  - Ion mobility spectrometry (IMS)
  - Data systems and software
reagents:
  - Matrix (CHCA, SA for MALDI)
  - Solvents (acetonitrile, water, formic acid)
  - Calibrants (ESI tuning mix, peptide standards)
  - Internal standards (isotopically labeled)
conditions:
  - ESI: positive/negative mode, 2-5 kV capillary
  - MALDI: laser energy, matrix preparation
  - Fragmentation: CID, HCD, ETD
  - Mass range: 100-10000 m/z typical
scale:
  analytical: 0.1-100 pmol
  intact_protein: 1-1000 pmol
yield:
  ionization_efficiency: variable
purity:
  mass_accuracy: <5 ppm (high resolution)
  resolution: 10000-1000000
quality_control:
  - Mass accuracy verification
  - Sensitivity check (LOD/LOQ)
  - System suitability
  - Calibration verification
  - Carry-over assessment
regulatory_requirements:
  - Method validation (ICH Q2)
  - System suitability
  - Mass accuracy specifications
  - Instrument qualification
  - Data integrity (21 CFR Part 11)
category: Characterization
tags: [mass-spectrometry, ESI, MALDI, molecular-weight, identity]
```

---

### Amino Acid Analysis

```yaml
id: CHR-022
process_name: Amino Acid Analysis (AAA)
description: >
  Quantitative determination of amino acid composition after complete
  hydrolysis (6N HCl, 110°C, 24h). Provides absolute quantification
  and composition verification. Gold standard for peptide/protein
  concentration determination and sequence confirmation.
equipment:
  - Amino acid analyzer (ion exchange + ninhydrin)
  - HPLC with pre-column derivatization (OPA, FMOC, AQC)
  - Hydrolysis tubes (vapor phase or liquid phase)
  - Vacuum hydrolysis system
  - Evaporator/concentrator
reagents:
  - Hydrolysis: 6N HCl (constant boiling)
  - Vapor phase: HCl/TFA mixture
  - Derivatization: OPA, FMOC-Cl, AQC
  - Internal standard: norleucine, norvaline
  - Amino acid standard mix
  - HPLC solvents
conditions:
  - Hydrolysis: 110°C, 24-72 hours
  - Vacuum: <100 mTorr
  - Derivatization: room temperature, 1-5 min
  - Analysis time: 30-60 min per sample
scale:
  analytical: 1-100 µg peptide
yield:
  hydrolysis_recovery: 85-100% (amino acid dependent)
  tryptophan: destroyed (separate analysis needed)
  cysteine: requires oxidation (cysteic acid)
purity:
  composition_accuracy: ±5-10%
quality_control:
  - Standard curve linearity
  - Replicate precision (RSD <5%)
  - Recovery studies
  - Blank controls
regulatory_requirements:
  - USP <1052> (biotechnology-derived articles)
  - EP 2.2.56
  - Method validation (accuracy, precision)
  - Reference standard qualification
category: Characterization
tags: [amino-acid-analysis, composition, quantification, hydrolysis]
```

---

### NMR Spectroscopy

```yaml
id: CHR-023
process_name: NMR Spectroscopy
description: >
  Nuclear magnetic resonance for detailed structural characterization.
  1D (1H, 13C) for purity and identity, 2D (COSY, TOCSY, NOESY, HSQC)
  for complete structure determination. Provides information on
  stereochemistry, dynamics, and intermolecular interactions.
equipment:
  - NMR spectrometer (300-900 MHz)
  - Sample preparation equipment
  - Cryoprobes (for sensitivity)
  - Autosamplers
  - Processing software (TopSpin, MestReNova)
reagents:
  - Deuterated solvents (D2O, DMSO-d6, CDCl3, TFE-d3)
  - Internal standards (TSP, DSS, TMS)
  - Water suppression reagents
conditions:
  - Temperature: 25-37°C (or variable)
  - Spectrometer frequency: 400-900 MHz
  - 1H scans: 16-512
  - 2D experiments: 2-24 hours
  - Sample concentration: 0.1-10 mM
scale:
  analytical: 0.5-10 mg
yield:
  structural_information: qualitative
purity:
  detection_limit: ~1% impurity
  chemical_shift_accuracy: ±0.01 ppm
quality_control:
  - Field frequency lock
  - Shimming (line shape)
  - Calibration (chemical shift reference)
  - Sensitivity (S/N ratio)
  - Reproducibility
regulatory_requirements:
  - Structure confirmation for NCE filing
  - ICH Q6A (identity testing)
  - Spectral documentation
  - Reference standard characterization
category: Characterization
tags: [NMR, structure, stereochemistry, 2D-NMR, conformation]
```

---

### Circular Dichroism

```yaml
id: CHR-024
process_name: Circular Dichroism (CD) Spectroscopy
description: >
  Measures differential absorption of left and right circularly polarized
  light to determine secondary structure content (α-helix, β-sheet, turns,
  random coil). Far-UV CD (190-250 nm) for backbone structure, near-UV CD
  (250-350 nm) for tertiary structure and aromatic environment.
equipment:
  - CD spectropolarimeter (JASCO, Applied Photophysics)
  - Temperature control unit (Peltier)
  - Cuvettes (0.01-1 cm path length)
  - Nitrogen purging system
  - Data analysis software
reagents:
  - Buffer: phosphate (low UV cutoff), Tris
  - Peptide concentration: 0.1-1 mg/mL
  - Solvent: water, TFE, SDS (for membrane peptides)
  - Denaturants (GdnHCl, urea)
conditions:
  - Far-UV: 190-250 nm
  - Near-UV: 250-350 nm
  - Temperature: 4-95°C (for melting curves)
  - Scan speed: 20-100 nm/min
  - Accumulations: 3-8 scans
  - Path length: 0.01-0.1 cm (concentration dependent)
scale:
  analytical: 50-500 µg
yield:
  structural_content: semi-quantitative
purity:
  helix_content_accuracy: ±5%
quality_control:
  - HT voltage check (<600 V)
  - Baseline correction
  - Protein concentration accuracy
  - Temperature calibration
regulatory_requirements:
  - Structure confirmation documentation
  - Batch-to-batch comparison
  - Stability-indicating method potential
  - Biophysical characterization dossier
category: Characterization
tags: [CD, secondary-structure, helix, sheet, conformation]
```

---

### X-ray Crystallography

```yaml
id: CHR-025
process_name: X-ray Crystallography
description: >
  Three-dimensional structure determination at atomic resolution (1-3 Å)
  from single crystal diffraction patterns. Provides complete atomic
  coordinates, B-factors, and electron density maps. Gold standard
  for high-resolution protein/peptide structure determination.
equipment:
  - X-ray source (rotating anode, synchrotron)
  - Crystal mounting equipment (cryo-tools)
  - Detector (CCD, CMOS, pixel array)
  - Crystal screening (robotic)
  - Computing cluster (for phasing/refinement)
reagents:
  - Crystallization screens (Hampton, Jena)
  - Cryoprotectants (glycerol, PEG, ethylene glycol)
  - Heavy atom derivatives (for phasing)
  - Seeding solutions
  - Protein at 5-50 mg/mL
conditions:
  - Crystallization: vapor diffusion (hanging/sitting drop)
  - Temperature: 4°C or 20°C
  - Screening: 96-well format, 0.1-1 µL drops
  - Optimization: grid screens around hits
  - Data collection: 100 K (cryo)
  - Resolution: 1.0-3.5 Å target
scale:
  crystallization: 1-50 mg protein
  data_collection: single crystal (~0.1-0.5 mm)
yield:
  structure_determination: 30-60% success rate
purity:
  resolution: 1.0-3.5 Å
  R-factor: 15-25%
  R-free: 18-28%
quality_control:
  - Crystal quality (mosaicity, diffraction limit)
  - Data completeness (>95%)
  - Multiplicity (>3x)
  - I/σ(I) (>2 in highest shell)
  - Structure validation (MolProbity)
regulatory_requirements:
  - PDB deposition for drug targets
  - Structure validation reports
  - ICH Q6A (identity confirmation)
  - Coordinate and structure factor submission
category: Characterization
tags: [X-ray, crystallography, 3D-structure, atomic-resolution, PDB]
```

---

## Formulation Processes

### Lyophilization

```yaml
id: FOR-026
process_name: Lyophilization (Freeze-Drying)
description: >
  Removal of water by freezing the formulation then sublimating ice under
  vacuum. Produces stable, dry powder with preserved structure and activity.
  Three phases: freezing, primary drying (sublimation), secondary drying
  (desorption). Standard for peptide pharmaceuticals requiring long shelf life.
equipment:
  - Lyophilizer (shelf freeze dryer)
  - Temperature-controlled shelves (-70 to +40°C)
  - Condenser (-80 to -40°C)
  - Vacuum pump (to 10 mTorr)
  - Vial loading/unloading systems
  - Process monitoring (Pirani, capacitance manometer)
reagents:
  - Excipients: mannitol, sucrose, trehalose, glycine
  - Bulking agents: mannitol, dextran
  - Surfactants: polysorbate 80 (0.01%)
  - Buffer: phosphate, histidine, citrate
  - Water for injection
conditions:
  - Freezing: -40 to -50°C, 1-3°C/min ramp
  - Annealing: -20 to -25°C (optional)
  - Primary drying: -25 to -35°C shelf, 50-200 mTorr
  - Secondary drying: +20 to +40°C, 50-200 mTorr
  - Total cycle time: 24-72 hours
scale:
  lab: 1-100 vials
  pilot: 100-10000 vials
  production: 10000-100000 vials
yield:
  reconstitution: <30 seconds (target)
  moisture: <1-3% w/w
purity:
  cake_appearance: intact, no collapse
  reconstitution_clarity: clear, no particles
quality_control:
  - Residual moisture (Karl Fischer)
  - Cake appearance (visual)
  - Reconstitution time
  - Potency (HPLC)
  - Particle size (if applicable)
  - Stability (accelerated)
regulatory_requirements:
  - Process validation (ICH Q8)
  - In-process monitoring
  - ICH Q1A (stability testing)
  - Sterility assurance (if aseptic)
  - Container closure integrity
category: Formulation
tags: [lyophilization, freeze-drying, stability, excipients]
```

---

### Spray Drying

```yaml
id: FOR-027
process_name: Spray Drying
description: >
  Conversion of liquid feed to dry powder by atomization into a hot
  drying gas. Rapid evaporation produces particles with controlled
  size, morphology, and density. Used for pulmonary delivery, encapsulation,
  and amorphous solid dispersion formulations.
equipment:
  - Spray dryer (Büchi, GEA, Niro)
  - Atomizer (rotary, nozzle, ultrasonic)
  - Drying chamber
  - Cyclone separator
  - Bag filter
  - Temperature and humidity sensors
reagents:
  - Peptide solution (1-30% solids)
  - Carrier agents: trehalose, mannitol, leucine
  - Stabilizers: polysorbate, PVA
  - Solvents: water, ethanol/water mixtures
conditions:
  - Inlet temperature: 100-200°C
  - Outlet temperature: 40-80°C
  - Feed rate: 1-100 mL/min
  - Atomization: 200-800 kPa (pressure nozzle)
  - Drying gas: nitrogen (for oxygen-sensitive)
scale:
  bench: 1-100 g
  pilot: 100 g - 10 kg
  production: 10-1000 kg
yield:
  process_yield: 50-85%
  moisture: <3-5% w/w
purity:
  particle_size: 1-10 µm (pulmonary)
  residual_solvent: <5000 ppm
quality_control:
  - Particle size distribution (laser diffraction)
  - Moisture content
  - Morphology (SEM)
  - Bulk/tapped density
  - Flow properties
  - Aerodynamic diameter (cascade impactor)
regulatory_requirements:
  - Process validation
  - Particle size specifications
  - Residual solvent limits (ICH Q3C)
  - Delivered dose uniformity
  - ICH Q1A stability
category: Formulation
tags: [spray-drying, particles, pulmonary, amorphous]
```

---

### Nanoparticle Formulation

```yaml
id: FOR-028
process_name: Nanoparticle Formulation
description: >
  Encapsulation of peptides in nanocarriers (10-1000 nm) for improved
  bioavailability, sustained release, and targeted delivery. Types include
  polymeric nanoparticles (PLGA, PLA), lipid nanoparticles (LNPs), solid
  lipid nanoparticles (SLN), and polymeric micelles.
equipment:
  - High-pressure homogenizer
  - Microfluidizer
  - Ultrasonicator (probe or bath)
  - Solvent evaporation setup
  - Dynamic light scattering (DLS) analyzer
  - Zeta potential analyzer
reagents:
  - Polymers: PLGA, PLA, PCL, chitosan, alginate
  - Lipids: DSPC, DOTAP, cholesterol, PEG-lipids
  - Surfactants: PVA, polysorbate 80, lecithin
  - Organic solvents: DCM, ethyl acetate, acetone
  - Crosslinkers: EDC, glutaraldehyde
conditions:
  - Nanoprecipitation: room temperature
  - Emulsion: 10000-30000 rpm (high shear)
  - Homogenization: 500-2000 bar
  - Microfluidization: 10000-30000 psi
  - Solvent evaporation: reduced pressure
scale:
  bench: 1-100 mL
  pilot: 100 mL - 10 L
  production: 10-1000 L
yield:
  encapsulation_efficiency: 30-95%
  process_yield: 60-90%
purity:
  particle_size: 10-500 nm (tunable)
  PDI: <0.2 (monodisperse)
  zeta_potential: -30 to +40 mV
quality_control:
  - Particle size (DLS, NTA)
  - PDI (polydispersity index)
  - Zeta potential
  - Encapsulation efficiency
  - In vitro release kinetics
  - Morphology (TEM, SEM)
  - Sterility
regulatory_requirements:
  - Nanoparticle characterization guidelines
  - ICH Q8 (formulation development)
  - Sterility assurance
  - Endotoxin limits
  - Container closure compatibility
category: Formulation
tags: [nanoparticles, PLGA, LNP, encapsulation, sustained-release]
```

---

### Liposome Formulation

```yaml
id: FOR-029
process_name: Liposome Formulation
description: >
  Encapsulation in lipid vesicles composed of phospholipid bilayers.
  Liposomes (50 nm - 5 µm) provide biocompatible delivery, membrane
  permeation enhancement, and controlled release. Types: multilamellar
  (MLV), unilamellar (SUV, LUV), and stealth (PEGylated).
equipment:
  - Thin-film evaporation setup
  - Extruder (Northern Lipids, Avanti)
  - High-pressure homogenizer
  - Ultrasonicator
  - Microfluidizer
  - DLS analyzer
reagents:
  - Phospholipids: DPPC, DSPC, DOPC, HSPC
  - Cholesterol
  - PEG-lipids: DSPE-PEG2000
  - Charged lipids: DOTAP, DOPS
  - Solvents: chloroform, methanol, ethanol
  - Buffers: PBS, HEPES, acetate
conditions:
  - Thin-film hydration: 50-65°C
  - Extrusion: through 50-200 nm polycarbonate membranes
  - Sonication: 20-60 min (bath), 1-10 min (probe)
  - Hydration: 1-24 hours
  - Temperature: above lipid Tm
scale:
  bench: 1-100 mL
  pilot: 100 mL - 10 L
  production: 10-500 L
yield:
  encapsulation_efficiency: 10-80% (peptide dependent)
  lipid_recovery: 80-95%
purity:
  particle_size: 50-500 nm
  lamellarity: controlled (MLV, LUV, SUV)
  PDI: <0.15
quality_control:
  - Particle size (DLS)
  - Encapsulation efficiency (dialysis, gel filtration)
  - Zeta potential
  - Lamellarity (cryo-TEM, 31P-NMR)
  - Lipid oxidation (peroxide value)
  - Leakage kinetics
regulatory_requirements:
  - Lipid qualification
  - Sterility
  - Endotoxin
  - ICH Q8 (formulation development)
  - Phase transition characterization
  - Accelerated stability
category: Formulation
tags: [liposomes, lipid-vesicles, encapsulation, controlled-release]
```

---

### Hydrogel Formulation

```yaml
id: FOR-030
process_name: Hydrogel Formulation
description: >
  Embedding of peptides in crosslinked hydrophilic polymer networks for
  sustained local delivery. Hydrogels (90-99% water) provide tissue-
  compatible matrices with tunable mechanical properties and degradation.
  Applications: wound healing, local cancer therapy, tissue engineering.
equipment:
  - Mixing vessels
  - UV crosslinking chambers
  - Rheometers (gel characterization)
  - Syringe-based delivery systems
  - 3D bioprinters
  - Lyophilizers (for storage)
reagents:
  - Polymers: PEG, hyaluronic acid, alginate, gelatin, chitosan
  - Crosslinkers: genipin, EDC/NHS, photoinitiators (Irgacure 2959)
  - Peptide (physical entrapment or covalent conjugation)
  - Buffer: PBS, HEPES
  - Ions: CaCl2 (for alginate)
conditions:
  - Chemical crosslinking: room temperature, 1-24 hours
  - Photo-crosslinking: UV 365 nm, 1-10 min
  - Ionic crosslinking: immediate
  - Temperature: 4-37°C
  - pH: 6.0-8.0
scale:
  bench: 1-100 mL
  pilot: 100 mL - 10 L
  production: 10-100 L
yield:
  entrapment_efficiency: 50-95%
  gel_yield: 80-95%
purity:
  gel_strength: 10-10000 Pa (G')
  swelling_ratio: 5-100x dry weight
  pore_size: 10-500 nm
quality_control:
  - Rheological properties (G', G'')
  - Swelling kinetics
  - Degradation rate
  - Peptide release profile
  - Sterility
  - Biocompatibility (cytotoxicity)
regulatory_requirements:
  - Biocompatibility (ISO 10993)
  - Sterility (terminal sterilization or aseptic)
  - Degradation product characterization
  - ICH Q8 (formulation development)
  - Local tolerance testing
category: Formulation
tags: [hydrogel, sustained-release, local-delivery, polymer-network]
```

---

## Quality Control Processes

### Purity Testing

```yaml
id: QC-031
process_name: Purity Testing (HPLC Analysis)
description: >
  Quantitative determination of peptide purity using high-performance
  liquid chromatography. RP-HPLC with UV detection at 214-220 nm is
  the primary method. Gradient elution separates the target peptide
  from impurities (deletion sequences, truncations, modifications).
equipment:
  - HPLC system (Agilent, Waters, Shimadzu)
  - Column: C18, 2.1-4.6 mm ID, 50-250 mm, 3-5 µm particle
  - UV/Vis detector (DAD preferred)
  - Autosampler
  - Column oven
reagents:
  - Mobile phase A: 0.1% TFA in water
  - Mobile phase B: 0.1% TFA in acetonitrile
  - Reference standard (qualified)
  - System suitability standard
conditions:
  - Gradient: 5-95% B
  - Flow rate: 0.2-1.0 mL/min
  - Temperature: 25-40°C
  - Detection: 214-220 nm
  - Injection volume: 1-20 µL
scale:
  analytical: 1-100 µg
yield:
  data_output: purity percentage
purity:
  quantification: 0.1-100%
  precision: RSD <2%
quality_control:
  - System suitability (plate count, tailing, resolution)
  - Linearity (r² >0.999)
  - Precision (injection, intermediate)
  - Accuracy (recovery 98-102%)
  - LOD/LOQ determination
  - Robustness testing
regulatory_requirements:
  - ICH Q2 (validation of analytical procedures)
  - ICH Q6A (specifications)
  - USP <621> (chromatography)
  - 21 CFR Part 11 (electronic records)
  - Reference standard qualification
category: Quality Control
tags: [purity, HPLC, RP-HPLC, quantitative, release-testing]
```

---

### Identity Testing

```yaml
id: QC-032
process_name: Identity Testing (MS Confirmation)
description: >
  Confirmation of peptide molecular weight and identity using mass
  spectrometry. ESI-MS or MALDI-TOF provides exact mass within ±0.1 Da.
  Tandem MS (MS/MS) confirms amino acid sequence. Required for release
  testing and batch-to-batch consistency verification.
equipment:
  - ESI-MS or MALDI-TOF
  - LC-MS system (for on-line confirmation)
  - Data analysis software
reagents:
  - Acetonitrile (LC-MS grade)
  - Water (LC-MS grade)
  - Formic acid (0.1%)
  - Matrix (CHCA for MALDI)
  - Calibrants
conditions:
  - ESI: positive mode, 2-5 kV
  - MALDI: CHCA matrix, 337/355 nm laser
  - Mass range: 100-10000 m/z
  - Resolution: >10000 (unit resolution minimum)
scale:
  analytical: 0.1-10 µg
yield:
  mass_accuracy: ±0.1 Da (ESI), ±0.5 Da (MALDI)
quality_control:
  - Mass accuracy verification
  - Sequence confirmation (MS/MS)
  - Reference standard comparison
  - System suitability
regulatory_requirements:
  - ICH Q6A (identity tests)
  - USP <1052>
  - Pharmacopoeia requirements
  - Batch release documentation
category: Quality Control
tags: [identity, mass-spectrometry, molecular-weight, confirmation]
```

---

### Potency Testing

```yaml
id: QC-033
process_name: Potency Testing (Bioassay)
description: >
  Measurement of biological activity relative to a reference standard.
  Cell-based assays, receptor binding, enzyme inhibition, or animal
  bioassays depending on mechanism of action. Results expressed as
  IU/mg or percentage of reference standard activity.
equipment:
  - Cell culture incubators
  - Microplate reader (absorbance, fluorescence, luminescence)
  - Flow cytometer
  - Receptor binding assay equipment
  - Animal facility (if in vivo)
reagents:
  - Reference standard (WHO international standard if available)
  - Cell lines (HEK293, CHO, specific reporter cells)
  - Substrates (for enzyme assays)
  - Detection reagents (MTT, AlamarBlue, luciferase)
  - Controls (positive, negative)
conditions:
  - Cell-based: 37°C, 5% CO2, 24-72 hours
  - Receptor binding: 4°C or 25°C, 1-4 hours
  - Dose-response: 6-8 concentrations
  - Replicates: minimum 3
scale:
  analytical: 1-100 µg per assay
yield:
  potency: IU/mg or % of reference
  relative_standard_deviation: <15%
quality_control:
  - Parallelism with reference standard
  - Dose-response curve fitting (4-parameter logistic)
  - Precision (inter-assay, intra-assay)
  - Specificity (no interference from excipients)
  - Linearity of dilution
regulatory_requirements:
  - ICH Q6B (specifications for biologics)
  - USP <1032>, <1033>, <1034>
  - Biological assay validation
  - Reference standard traceability
  - Potency assignment methodology
category: Quality Control
tags: [potency, bioassay, biological-activity, mechanism-of-action]
```

---

### Stability Testing

```yaml
id: QC-034
process_name: Stability Testing (ICH Guidelines)
description: >
  Systematic testing to establish shelf life and storage conditions.
  Follows ICH Q1A-Q1E guidelines with accelerated (40°C/75% RH) and
  long-term (25°C/60% RH) conditions. Monitors purity, potency,
  appearance, moisture, and degradation products over time.
equipment:
  - Stability chambers (25°C/60% RH, 30°C/65% RH, 40°C/75% RH)
  - HPLC systems
  - Mass spectrometers
  - Karl Fischer titrator
  - pH meters
  - Visual inspection equipment
reagents:
  - Reference standards
  - HPLC mobile phases
  - Karl Fischer reagent
  - Degradation product standards (if available)
conditions:
  - Long-term: 25°C ± 2°C / 60% RH ± 5%
  - Intermediate: 30°C ± 2°C / 65% RH ± 5%
  - Accelerated: 40°C ± 2°C / 75% RH ± 5%
  - Photostability: ICH Q1B (Option 2)
  - Freeze-thaw: -20°C to 25°C, 3 cycles
  - Time points: 0, 1, 2, 3, 6, 9, 12, 18, 24, 36 months
scale:
  analytical: 1-100 mg per time point
yield:
  data_output: stability profile
quality_control:
  - Appearance (color, clarity, particulates)
  - Purity (HPLC)
  - Potency (bioassay)
  - Moisture (Karl Fischer)
  - pH
  - Degradation products
  - Container closure integrity
regulatory_requirements:
  - ICH Q1A (stability testing)
  - ICH Q1B (photostability)
  - ICH Q1C (new dosage forms)
  - ICH Q1E (evaluation of data)
  - ICH Q5C (biological products)
  - WHO stability guidelines
  - FDA/EMA stability guidance
category: Quality Control
tags: [stability, ICH, shelf-life, accelerated, long-term]
```

---

### Sterility Testing

```yaml
id: QC-035
process_name: Sterility Testing (Microbial Limits)
description: >
  Verification that sterile peptide products contain no viable
  microorganisms. Membrane filtration (preferred) or direct inoculation
  into growth media (tryptic soy broth, fluid thioglycolate). Also
  includes endotoxin testing (LAL), bioburden, and environmental monitoring.
equipment:
  - Sterility testing isolator or laminar flow hood
  - Membrane filtration apparatus
  - Incubators (20-25°C, 30-35°C)
  - LAL endotoxin reader (kinetic turbidimetric, chromogenic)
  - Colony counter
  - Environmental monitoring equipment (air samplers)
reagents:
  - Growth media: TSB (tryptic soy broth), FTM (fluid thioglycolate)
  - Membrane filters: 0.45 µm, 47 mm diameter
  - LAL reagent (Limulus amebocyte lysate)
  - Endotoxin standard (CSE, RSE)
  - Validation controls (growth promotion, bacteriostasis/fungistasis)
conditions:
  - TSB incubation: 20-25°C, 14 days
  - FTM incubation: 30-35°C, 14 days
  - LAL incubation: 37°C ± 1°C, 60 min (kinetic)
  - Environmental monitoring: 30-60 min sampling
scale:
  analytical: 10-100 mL per test
yield:
  sterility_assurance: SAL 10⁻⁶ (terminal sterilization)
  aseptic: SAL 10⁻³ to 10⁻⁴
quality_control:
  - Growth promotion (media qualification)
  - Bacteriostasis/fungistasis testing
  - Positive controls
  - Negative controls
  - Environmental monitoring trends
  - Endotoxin limit: 5 EU/kg (parenteral)
regulatory_requirements:
  - USP <71> (sterility tests)
  - USP <85> (bacterial endotoxins)
  - EU GMP Annex 1 (manufacture of sterile products)
  - FDA 21 CFR 211 (cGMP)
  - ICH Q6A (specifications)
  - ISO 14644 (cleanroom classification)
  - Environmental monitoring program
category: Quality Control
tags: [sterility, endotoxin, LAL, microbial, aseptic]
```

---

## Process Categories Summary

### Synthesis (10 processes)

| ID | Process | Key Advantage |
|---|---|---|
| SYN-001 | SPPS | Industry standard, automated |
| SYN-002 | LPPS | Large scale, solution phase |
| SYN-003 | Recombinant | Complex proteins, PTMs |
| SYN-004 | Cell-free | Non-natural AAs, rapid |
| SYN-005 | Enzymatic | Green chemistry, stereocontrol |
| SYN-006 | Microwave | Fast, difficult sequences |
| SYN-007 | Flow Chemistry | Continuous, PAT integration |
| SYN-008 | Fragment Condensation | Long peptides, convergent |
| SYN-009 | Native Chemical Ligation | Proteins, chemoselective |
| SYN-010 | Click Chemistry | Conjugation, bioconjugation |

### Purification (10 processes)

| ID | Process | Key Advantage |
|---|---|---|
| PUR-011 | RP-HPLC | High resolution, polishing |
| PUR-012 | IEX | Charge-based, scalable |
| PUR-013 | SEC | Aggregate removal, desalting |
| PUR-014 | Affinity | Highly selective, one-step |
| PUR-015 | Membrane Filtration | Scalable, buffer exchange |
| PUR-016 | Crystallization | Solid form, high purity |
| PUR-017 | Precitation | Cost-effective, capture |
| PUR-018 | Extraction | Hydrophobic impurity removal |
| PUR-019 | Preparative Chromatography | Industrial scale |
| PUR-020 | Electrophoresis | High resolution analysis |

### Characterization (5 processes)

| ID | Process | Key Information |
|---|---|---|
| CHR-021 | Mass Spectrometry | Molecular weight, sequence |
| CHR-022 | Amino Acid Analysis | Composition, quantification |
| CHR-023 | NMR Spectroscopy | Stereochemistry, conformation |
| CHR-024 | Circular Dichroism | Secondary structure |
| CHR-025 | X-ray Crystallography | 3D atomic structure |

### Formulation (5 processes)

| ID | Process | Key Application |
|---|---|---|
| FOR-026 | Lyophilization | Long-term stability |
| FOR-027 | Spray Drying | Pulmonary, amorphous |
| FOR-028 | Nanoparticle Formulation | Sustained release, targeting |
| FOR-029 | Liposome Formulation | Membrane permeation |
| FOR-030 | Hydrogel Formulation | Local sustained delivery |

### Quality Control (5 processes)

| ID | Process | Key Parameter |
|---|---|---|
| QC-031 | Purity Testing | Purity % |
| QC-032 | Identity Testing | Molecular weight, sequence |
| QC-033 | Potency Testing | Biological activity |
| QC-034 | Stability Testing | Shelf life |
| QC-035 | Sterility Testing | Microbial limits |

---

## Regulatory Reference

| Guideline | Scope |
|---|---|
| ICH Q1A-E | Stability testing |
| ICH Q2 | Analytical method validation |
| ICH Q3A-D | Impurities (drug substance/product, solvents, elements) |
| ICH Q5A-E | Quality of biotechnological products |
| ICH Q6A/B | Specifications |
| ICH Q7 | GMP for APIs |
| ICH Q8 | Pharmaceutical development |
| ICH Q9 | Quality risk management |
| ICH Q10 | Pharmaceutical quality system |
| ICH Q11 | Development and manufacture of drug substances |
| USP <71> | Sterility tests |
| USP <85> | Bacterial endotoxins |
| USP <621> | Chromatography |
| USP <1052> | Biotechnology-derived articles |
| FDA 21 CFR 210/211 | cGMP |
| FDA 21 CFR Part 11 | Electronic records |
| EU GMP Annex 1 | Sterile products |
| EU GMP Annex 2 | Biological products |
| ISO 14644 | Cleanroom classification |
| ISO 10993 | Biocompatibility |
